Siv Gyda Aanes
LightNews LightNews
banner
sivgyda.bsky.social
Siv Gyda Aanes
@sivgyda.bsky.social
210 followers 430 following 6 posts
MD Oncology in Northern Norway, special interest in thoracic oncology, loves football, beagles, QI, patient Safety and saunas❤️!
Posts Replies Media Videos
Pinned
sivgyda.bsky.social
Siv Gyda Aanes @sivgyda.bsky.social · Nov 19
Happy to present our review on facilitators and barrieres for implementing digital #ePRO in routine #cancer care- in #ESMO Real World Data and Digital Oncology! Open access link here - www.esmorwd.org/action/showP...
Reposted by Siv Gyda Aanes
drjnaidoo.bsky.social
Long-Term Toxicity of Immune Checkpoint Inhibitors @jama.com

Here, our stellar fellow #ChrisCronin charts a roadmap of how to quantitate the nuanced toxicities of IO from irAEs to time toxicity towards IO survivorship

#CancerCentreIre @oncoalert.bsky.social #LCSM
jamanetwork.com/journals/jam...
Long-Term Toxicity of Immune Checkpoint Inhibitors
This Viewpoint discusses the need to quantify the long-term adverse effects of immune checkpoint inhibitors, particularly immune-related adverse effects, which are not universally dose dependent, limi...
jamanetwork.com
February 27, 2025 at 9:32 PM
Reposted by Siv Gyda Aanes
iaslc.bsky.social
After years of raising awareness, Dr. Bryant Lin was diagnosed with stage IV EGFR+ lung cancer. In the new #LungCancerConsidered episode, he talks with @stephenvliu.bsky.social about patient experience, treatment, and teaching cancer care.

🎧 Listen: bit.ly/LinTMLC
Interview with Dr. Bryant Lin: Teaching My Lung Cancer | IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Dr. Bryant Lin, Clinical Professor of Medicine at Stanford University and co-founder ...
bit.ly
May 6, 2025 at 1:48 PM
Reposted by Siv Gyda Aanes
ascopost.bsky.social
ASCO and Google Cloud have introduced an AI-powered tool designed to streamline cancer care documentation, with potential to reduce administrative burden and improve workflow.
🔗 ascopost.com/news/may-202...
#Oncology #HealthIT
May 21, 2025 at 7:38 PM
Reposted by Siv Gyda Aanes
bodoglimt.bsky.social
I går stod vi sammen. På tribunen. På banen. I hjertet. Takk💛
April 11, 2025 at 9:52 AM
Reposted by Siv Gyda Aanes
glimtstickers.bsky.social
Blir du med @glimtivest.bsky.social på historiens aller første @bodoglimt.bsky.social Kvinner-kamp på Brann stadion i morgen, så vanker det stickers 🙏
April 11, 2025 at 10:50 AM
Reposted by Siv Gyda Aanes
bodoglimt.bsky.social
Avreise til Athen 🇬🇷
March 11, 2025 at 5:14 PM
Reposted by Siv Gyda Aanes
drjnaidoo.bsky.social
Are you a European clinician🇪🇺 who treats pts with IO & manages #irAEs? Join us in creating a pan-European vision for #irAE care🌍

Complete this short set of q’s on irAE care in your institution & country: vub.fra1.qualtrics.com/jfe/form/SV_...

@oncoalert.bsky.social
January 24, 2025 at 11:03 PM
Reposted by Siv Gyda Aanes
drjnaidoo.bsky.social
IASLC #WCLC2025 is upon us! Your co-chairs cannot wait to welcome you #NoemiReguart 🇪🇸 #IsabelleOpitz🇨🇭 #UmbertoMalapelle 🇮🇹 & a familiar face from🇮🇪

Registration & abstract submissions are OPEN!

Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC
February 13, 2025 at 10:15 PM
Reposted by Siv Gyda Aanes
drjnaidoo.bsky.social
Interesting new compound in the KRAS world, BBO-8520 @theaacr.bsky.social
- First-In-Class inhibitor of KRAS G12Ci in GTP-Bound (ON)+GDP-Bound (OFF) states
- Ph I ONKORAS-101 trial ongoing, BBO-8520+\- pembro

@oncoalert.bsky.social @kraskickers.bsky.social #LCSM

aacrjournals.org/cancerdiscov...
Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
Abstract. Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP-bound (ON) form. T...
aacrjournals.org
February 17, 2025 at 10:33 PM
Reposted by Siv Gyda Aanes
doctorswithoutborders.org
Hi Bluesky community! We're excited to be here to share important humanitarian stories.

Would you let your network know where to find us? This is just a snapshot of what we stand for as an emergency medical organization:
Text reads: Stand with refugees and people forced from home. Stand with people demanding access to safe abortion care. Stand with people whose health is impacted by climate change. Stand with people facing health inequities due to racism and discrimination. Stand with vulnerable people everywhere.
January 24, 2025 at 4:45 PM
Reposted by Siv Gyda Aanes
theaacr.bsky.social
AACR Cancer Disparities Progress Report: Clinical trials are critical to determining the safety and efficacy of new treatments, but limited diversity among participants hinders progress in cancer care for all patient populations. https://buff.ly/3XgMcoh
February 23, 2025 at 6:14 PM
Reposted by Siv Gyda Aanes
rielymd.bsky.social
Full publication of phase 3 that compared mobocertinib to platinum-pem in EGFR exon 20 lung cancer. Ultimately led to mobocertinib removal from market. This remains the goal: new drugs should be better than chemotherapy. We should not settle for adding to chemotherapy!
ascopubs.org/doi/pdf/10.1...
kaplan-meier curves showing (A) equivalent PFS for mobocertinib and chemotherpy (C) improved duration of response for mobocertinib
January 30, 2025 at 2:20 PM
Reposted by Siv Gyda Aanes
erikahamilton9.bsky.social
Love Dr. Burstein caveat to this slide...but does suggest that maybe the sweet spot 🎯 is:

BOTH - 1️⃣ CDK switch (and continued blockade) AND 2️⃣ novel next-gen endocrine agent.

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 11, 2024 at 3:45 PM
Reposted by Siv Gyda Aanes
bodoglimt.bsky.social
𝗞𝗔𝗠𝗣𝗗𝗔𝗚

🏆 Europa League
🗓️ Kampdag 5
🆚 Manchester United
🕕 21:00 CET
🏟️ Old Trafford
ℹ️ glimt.no
📺 Viaplay
📻 Radio 3 Bodø
November 28, 2024 at 9:03 AM
Reposted by Siv Gyda Aanes
bodoglimt.bsky.social
Slik starter Glimt i Manchester 🤩
November 28, 2024 at 7:07 PM
Reposted by Siv Gyda Aanes
nlbigas.bsky.social
Only a subset of patients respond to immunotherapy

Why? Which ones?

We conducted an unbiased analysis of response biomarkers and found that hundreds of possible biomarkers collapse into five latent, orthogonal factors that underlie immunotherapy response.

www.nature.com/articles/s41...
November 27, 2024 at 2:13 PM
Reposted by Siv Gyda Aanes
maryamlustberg.bsky.social
Grade 1-2 treatment-related irAEs in the first cycle of therapy were associated with longer overall survival compared to no irAEs from checkpoint inhibitors. #survonc #supponc

doi.org/10.1093/jnci...
First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors
AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate
doi.org
November 27, 2024 at 9:46 PM
Reposted by Siv Gyda Aanes
helenbevan.bsky.social
New article in MIT Sloan Management Review shows how leaders who influence through collaboration get better outcomes from decisions than leaders who try to "sell" their ideas. Getting the support of others without formal authority works better than persuasion:
sloanreview.mit.edu/article/why-...
.
November 27, 2024 at 8:14 PM
Reposted by Siv Gyda Aanes
msf.ca
#FollowFriday: Thank you to the community for your incredible support and for helping us grow!

This is the first Friday since our recent spike in followers, we’d like to highlight a few of our staff profiles for you to explore and follow.

Keep reading to learn more about some of our staff. 🧵⤵️
November 22, 2024 at 5:01 PM
sivgyda.bsky.social
Thrilled to attend #onkologiskforum2024 Bergen, Norway! Today kick off with great session at @NLCG (Norwegian Lung Cancer Group) discussing national Lung cancer screening, MDT, exciting clinical trials and news from Nordic Thoracic Oncology Group, ntog.org! 🤍
ntog.org
November 20, 2024 at 10:53 PM
Reposted by Siv Gyda Aanes
n8pennell.bsky.social
How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice ascopubs.org/doi/10.1200/... #LCSM
How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice
Until the early 2000s, advanced or metastatic non–small cell lung cancer (NSCLC) was treated as a single disease with all histologic subtypes treated alike with standard chemotherapy agents. Over the ...
ascopubs.org
November 18, 2024 at 12:38 PM
Reposted by Siv Gyda Aanes
stephenvliu.bsky.social
ASCO has released an updated Rapid Recommendation for stage III NSCLC in JCO Oncology Practice. Update now includes targeted therapy: consolidation osimertinib after chemoradiation for #EGFR NSCLC, adjuvant osimertinib or alectinib for resected EGFR or ALK NSCLC. #LCSM

ascopubs.org/doi/10.1200/...
Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights | JCO Oncology Practice
ascopubs.org
November 19, 2024 at 2:20 AM
Reposted by Siv Gyda Aanes
ranaawdish.bsky.social
Is sharing our writing a thing here? 😊
Proud of this piece because it represents the work of so many trying to make medicine and communication better for our patients. #MedSky
www.mayoclinicproceedings.org/action/showP...
November 19, 2024 at 3:42 PM
Reposted by Siv Gyda Aanes
drjnaidoo.bsky.social
Superb opinion piece on PCI in SCLC: do we need it in the IO era?

Key points:
- PCI optional in ES SCLC IO trials
- MRI surveillance acceptable in non IO era
- in LS SCLC, Adriatic showed PCI beneficial in IO & non IO arms

#LCSM #MedSky #OncSky

www.sciencedirect.com/science/arti...
November 16, 2024 at 9:26 PM
Reposted by Siv Gyda Aanes
drjnaidoo.bsky.social
'TrialGPT' A new chatGPT for clinical trials @natureportfolio.bsky.social:

- 3 steps: TrialGPT-Retrieval, TrialGPT-Matching, TrialGPT-Ranking
- Retrieval identified 90% suitable trials
- 42% time-saving in matching a patient to a trial

Like, wow
#MedSky #OncSky #LCSM
www.nature.com/articles/s41...
Matching patients to clinical trials with large language models - Nature Communications
Patient recruitment is challenging for clinical trials. Here, the authors introduce TrialGPT, an end-to-end framework for zero-shot patient-to-trial matching with large language models.
www.nature.com
November 18, 2024 at 5:35 PM